The field has made major strides in defining the GAIN of function effects on the AR cistrome and transcriptional program associated with prostate tumorigenesis, including redistribution of AR to enhancers enriched for FOXA1 and HOXB13 motifs3–6,20. This evidence concerns the gene FOXA1 and medical procedure.